$GDERF

Galderma Group AG/ADR

Galderma is a dermatology company based in Zug, Switzerland, serving markets worldwide. Its business covers aesthetic injectables, dermatological skincare and therapeutic dermatology. Its brands include Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac and Loceryl.

No enriched coverage for $GDERF in the last 7 days.

No SEC Form 4 filings for $GDERF in the last 30 days.

See all $GDERF insider activity →
Med

Galderma Expands Relfydess Reach With China Approval For Frown Lines

Galderma (GDERF) received China approval for Relfydess, a neuromodulator for frown lines. Supported by clinical data, it's the first ready-to-use liquid in China. The approval expands Galderma's portfolio in a growing market. GDERF stock closed at $220.14, up 10.82%.

Key deals this week: International Paper, IonQ, Bumble, and more

Varonis Systems (VRNS) rose 2.5% after Proofpoint agreed to acquire it for ~$6.3B. International Paper (IP) gained 7.4% on reports of potential bids for its European packaging business. CCC (CCC) will be acquired for ~$6.1B, Galderma (GALDY) will buy ZO Skin Health for $1.5B, and Bumble (BMBL) surged 57% on a $1.3B acquisition deal. IonQ (IONQ) is acquiring Elisity for up to $1.3B, and STERIS (STE) will buy Xodus Medical for $2.1B.

GDERF sentiment & insider activity

Recent GDERF coverage spans regulation, mergers & acquisitions and earnings.

What's driving GDERF

  • Approval expands Galderma's aesthetic portfolio in a large market, likely boosting sales outlook.

    rttnews.com · Oct 23, 2026

  • Galderma Group reported Q3 sales growth of 26.6% to $1.63 billion, driven by strong performance across regions and product categories. The company raised its FY26 sales growth outlook to 22.5-23.5% from 19-21%, while maintaining a Core EBITDA margin target of 26%. Shares rose 4.07% in Switzerland.

    rttnews.com · Oct 22, 2026

  • Varonis Systems (VRNS) rose 2.5% after Proofpoint agreed to acquire it for ~$6.3B. International Paper (IP) gained 7.4% on reports of potential bids for its European packaging business. CCC (CCC) will be acquired for ~$6.1B, Galderma (GALDY) will buy ZO Skin Health for $1.5B, and Bumble (BMBL) surged 57% on a $1.3B acquisition deal. IonQ (IONQ) is acquiring Elisity for up to $1.3B, and STERIS (STE) will buy Xodus Medical for $2.1B.

    tradingview.com · Oct 17, 2026

  • Galderma Group AG (GALD.SW, GALDY) will acquire ZO Skin Health from Blackstone Inc. (BX) for $1.5 billion, expected to close by early 2027. The deal will be funded through cash and bank financing, adding to Galderma's dermatological skincare portfolio. ZO Skin Health reported $330 million in net sales in the year ended June 2026.

    rttnews.com · Oct 14, 2026

  • EU regulatory approval expands Galderma’s injectable aesthetics portfolio and supports incremental demand expectations in facial shaping.

    rttnews.com · Aug 11, 2026

AlphAI scores every news story that mentions GDERF with an AI model for sentiment and relevance, and aggregates insider trades from Galderma Group AG/ADR's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $GDERF

Score

Key deals this week: International Paper, IonQ, Bumble, and more

Varonis Systems (VRNS) rose 2.5% after Proofpoint agreed to acquire it for ~$6.3B. International Paper (IP) gained 7.4% on reports of potential bids for its European packaging business. CCC (CCC) will be acquired for ~$6.1B, Galderma (GALDY) will buy ZO Skin Health for $1.5B, and Bumble (BMBL) surged 57% on a $1.3B acquisition deal. IonQ (IONQ) is acquiring Elisity for up to $1.3B, and STERIS (STE) will buy Xodus Medical for $2.1B.

$GALDYHighAI 9/10

Galderma To Acquire ZO Skin Health For $1.5 Bln

Galderma Group AG (GALD.SW, GALDY) will acquire ZO Skin Health from Blackstone Inc. (BX) for $1.5 billion, expected to close by early 2027. The deal will be funded through cash and bank financing, adding to Galderma's dermatological skincare portfolio. ZO Skin Health reported $330 million in net sales in the year ended June 2026.

$GDERFMedAI 8/10

Galderma Wins EU Nod For Restylane Shaype In Facial Shaping

Galderma Group (GDERF) said the EU approved Restylane Shaype, a hyaluronic acid injectable for temporary chin augmentation under the EU Medical Device Regulation. The company cited clinical results showing 83% improved structure at 3 months and 66% at 12 months. Galderma noted Restylane Shaype uses NASHA HD and that its stock closed at $228.55, up 3.91%.

$GDERFMedAI 8/10

Galderma Provides FDA Progress Update On RelabotulinumtoxinA Submission

Galderma said the U.S. FDA issued a Complete Response Letter for its BLA submission for relabotulinumtoxinA (Relfydess). The FDA cited manufacturing site inspection observations and requests to optimize analytical methods; Galderma said safety/efficacy sections had no deficiencies. Galderma plans corrective actions and continued FDA dialogue. GDERF shares closed at $238.05, up 12.95% Tuesday.

Related tickers